Oncotarget · 2015 · 52 citations · 24 references
MedicineNuclear MedicineOncologyMolecular ImagingMolecular OncologyNeoplasiaKidney CancerMolecular Imaging In OncologyRenal Cell CarcinomaRenal ImagingRenal Nuclear ImagingTumor ImagingCarbonic Anhydrase InhibitorsMolecular Imaging TracersRadioligand ImagingRenal Cell Carcinoma ImagingSingle-photon EmissionSingle-photon Emission Computed Tomography TracersTargeted Molecular Imaging AgentsTargeted Radionuclide Imaging
// Xing Yang 1, * , Il Minn 1, * , Steven P. Rowe 1 , Sangeeta Ray Banerjee 1 , Michael A. Gorin 2 , Mary Brummet 1 , Hye Soo Lee 1 , Soo Min Koo 1 , Polina Sysa-Shah 1 , Ronnie C. Mease 1 , Sridhar Nimmagadda 1 , Mohamad E. Allaf 2 , Martin G. Pomper 1 1 Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA 2 The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA * These authors have contributed equally to this work Correspondence to: Martin G. Pomper, e-mail: mpomper@jhmi.edu Xing Yang, e-mail: xyang45@jhmi.edu Keywords: CAIX, single photon emission computed tomography, molecular imaging, renal cell carcinoma, indium-111 Received: May 31, 2015 Accepted: September 03, 2015 Published: September 16, 2015 ABSTRACT We developed a new scaffold for radionuclide-based imaging and therapy of clear cell renal cell carcinoma (ccRCC) targeting carbonic anhydrase IX (CAIX). Compound XYIMSR-01 , a DOTA-conjugated, bivalent, low-molecular-weight ligand, has two moieties that target two separate sites on CAIX, imparting high affinity. We synthesized [ 111 In] XYIMSR-01 in 73.8–75.8% (n = 3) yield with specific radioactivities ranging from 118 – 1,021 GBq/μmol (3,200–27,600 Ci/mmol). Single photon emission computed tomography of [ 111 In] XYIMSR-01 in immunocompromised mice bearing CAIX-expressing SK-RC-52 tumors revealed radiotracer uptake in tumor as early as 1 h post-injection. Biodistribution studies demonstrated 26% injected dose per gram of radioactivity within tumor at 1 h. Tumor-to-blood, muscle and kidney ratios were 178.1 ± 145.4, 68.4 ± 29.0 and 1.7 ± 1.2, respectively, at 24 h post-injection. Retention of radioactivity was exclusively observed in tumors by 48 h, the latest time point evaluated. The dual targeting strategy to engage CAIX enabled specific detection of ccRCC in this xenograft model, with pharmacokinetics surpassing those of previously described radionuclide-based probes against CAIX.
24
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2015 · 11.9K citations · Full text